According to Zacks, “Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. “
Several other analysts have also issued reports on the company. ValuEngine raised Immunic from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Chardan Capital initiated coverage on Immunic in a research note on Monday, August 12th. They issued a “buy” rating and a $40.00 target price for the company.
Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.80). On average, analysts anticipate that Immunic will post -3.39 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Omega Fund Management LLC purchased a new stake in Immunic in the second quarter worth approximately $15,731,000. Independent Advisor Alliance purchased a new stake in Immunic in the second quarter worth approximately $804,000. BlackRock Inc. purchased a new stake in Immunic in the second quarter worth approximately $145,000. Vanguard Group Inc. purchased a new stake in Immunic in the second quarter worth approximately $132,000. Finally, Tower Research Capital LLC TRC purchased a new stake in Immunic in the second quarter worth approximately $33,000.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.